Stock Financial Ratios

HTGM / HTG Molecular Diagnostics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)24.95
Enterprise Value ($M)-1.31
Book Value ($M)-5.59
Book Value / Share-0.79
Price / Book-5.73
NCAV ($M)8.43
NCAV / Share1.19
Price / NCAV7.03
Income Statement (mra) ($M)
Net Income-26.04
Balance Sheet (mrq) ($M)
Cash & Equivalents9.05
Cash / Share1.27
Quick Ratio1.36
Current Ratio1.51
Management Effectiveness (mra)
Return on Invested Capital (ROIC)4.66
Return on Assets (ROA)-1.41
Return on Equity (ROE)4.66
Identifiers and Descriptors
Central Index Key (CIK)1169987
Industry Groups
SIC 3826 - Laboratory Analytical Instruments
Share Statistics
Common Shares Outstanding (M)12.51
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Other Non Current Per Share0.00
Property Plant And Equipment Net Per Share0.46
Inventory Work In Progress Per Share0.00
Equity Per Share-0.64
Treasury Stock Per Share0.00
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Retained Earnings Per Share-18.65
Accumulated Depreciation And Depletion Per Share0.42
Cash Per Share1.27
Property Plant And Equipment Gross Per Share0.88
Liabilities And Stock Equity Per Share2.42
Liabilities Other Non Current Per Share0.07
Intangibles Per Share0.00
Goodwill Per Share0.00
Liabilities Current Per Share1.90
Assets Per Share2.42
Property Plant And Equipment Per Share0.46
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Inventory Finished Goods Per Share0.05
Inventory Raw Materials Per Share0.15
Inventory Per Share0.18
Long Term Debt Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Accounts Receivable Per Share0.44
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash And Equivalents Per Share1.27
Liabilities Per Share3.06
Assets Current Per Share1.97
Additional Paid In Capital Per Share18.01

Stock Research Report

HTG Molecular is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. Its technology can be used throughout that range of applications, which is just one of its many benefits. Its focus is on clinical applications. Its primary customer segments include biopharmaceutical companies, academic research centers and molecular testing laboratories.

Historically, molecular profiling has faced several technical challenges in clinical applications. These include (i) limited “multiplexing,” which means only a few biomarkers could be tested in a single sample; (ii) the need for vast amount...

Click for full article

Related News Stories

Your Daily Pharma Scoop: Portola Upside, Novartis Reports Positive Cosentyx Data, Keryx Tumbles

2017-11-09 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (482-4)

HTG Molecular Diagnostics' (HTGM) CEO T. J. Johnson on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good day, and welcome to the HTG Molecular Diagnostics’ Third Quarter 2017 Earnings Call. Today’s conference is being recorded. There will be a question-and-answer session at the end of today’s presentation and instructions on how to ask the questions will be given at that time. (29-1)

HTG Molecular Diagnostics' (HTGM) CEO T. J. Johnson on Q2 2017 Results - Earnings Call Transcript

2017-08-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the HTG Molecular Diagnostics’ Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference maybe recorded. (0-1)

BRIEF-HTG Molecular Diagnostics Inc enters statement of work with subsidiary of QIAGEN N.V

2017-06-14 reuters
* HTG Molecular Diagnostics Inc - effective June 14, co entered statement of work with subsidiary of Qiagen N.V

CUSIP: 40434H104